Central nervous system health supplement

Patent metadata

Field	Value
Publication number	US-12403124-B2
Application number	US-202117644069-A
Country	US
Kind code	B2
Filing date	Dec 13, 2021
Priority date	Dec 29, 2020
Publication date	Sep 2, 2025
Grant date	Sep 2, 2025

Abstract

An orally administered composition positively mitigates the progression of central nervous system diseases such as Alzheimer's, Parkinson's and Multiple Sclerosis. The composition consists of a lipid based blood brain barrier transport medium (Base Transport Sub-Formula) to which other elements (Functional Targeting Compound) may be integrated to mediate specific chemo-neurological dysfunction. It may be administered through the mouth as droplets a spray medium or a chewable tablet.

First claim

What is claimed is:

1. A composition comprising:
sterubin; and
a pharmaceutically or physiologically-acceptable carrier;
wherein the composition is in a form adapted for sublingual administration of a dosage of the composition of 300 mg;
wherein the composition contains:
sterubin-bio-concentrated, yerba santa (11.2 wt. %);
gamma aminobutyric acid (10.7 wt. %);
tauroursodeoxycholic acid (10.7 wt. %);
glutathione (9.7 wt. %);
nicotinamide mononucleotide (9.5 wt. %);
alpha-glyceryl phosphorylcholine (8.5 wt. %);
5-hydroxytryptophan (5.5 wt. %);
phosphatidylserine (4.8 wt. %);
star anis (2.5 wt. %);
omega oil (11.5 wt. %);
glycerin (11.4 wt. %);
monk fruit (2.8 wt. %); and
magnesium stearate (1.2 wt. %).

2. The composition of claim 1 , in a form of a chewable tablet.

3. The composition of claim 1 , in a form of a spray for oral administration.

4. The composition of claim 1 , in a form adapted to be delivered to a patient by inhalation in a form of a vapor, a mist, or an aerosol.

5. The composition of claim 1 , in a form of a pharmaceutical composition, a dietary supplement, or a health supplement.

6. A method of treatment of a central nervous system disease selected from the group consisting of Parkinson's disease, multiple sclerosis, and dementia, comprising:
administering, to a patient in need thereof, an effective amount of sterubin;
wherein the sterubin is administered in a form adapted for sublingual administration of a dosage of a composition of 300 mg;
wherein the composition contains:
sterubin-bio-concentrated, yerba santa (11.2 wt. %);
gamma aminobutyric acid (10.7 wt. %);
tauroursodeoxycholic acid (10.7 wt. %);
glutathione (9.7 wt. %);
nicotinamide mononucleotide (9.5 wt. %);
alpha-glyceryl phosphorylcholine (8.5 wt. %);
5-hydroxytryptophan (5.5 wt. %);
phosphatidylserine (4.8 wt. %);
star anis (2.5 wt. %);
omega oil (11.5 wt. %);
glycerin (11.4 wt. %);
monk fruit (2.8 wt. %); and
magnesium stearate (1.2 wt. %).

7. The method of claim 6 , wherein the dementia is selected from the group consisting of Alzheimer's disease and lewy body dementia.

8. A method of ameliorating or slowing onset of a condition characterized by formation of amyloid plaque and/or tau plaque, comprising:
administering, to a patient in need thereof, an effective amount of sterubin;
wherein the sterubin is administered in a form adapted for sublingual administration of a dosage of a composition of 300 mg;
wherein the composition contains:
sterubin-bio-concentrated, yerba santa (11.2 wt. %);
gamma aminobutyric acid (10.7 wt. %);
tauroursodeoxycholic acid (10.7 wt. %);
glutathione (9.7 wt. %);
nicotinamide mononucleotide (9.5 wt. %);
alpha-glyceryl phosphorylcholine (8.5 wt. %);
5-hydroxytryptophan (5.5 wt. %);
phosphatidylserine (4.8 wt. %);
star anis (2.5 wt. %);
omega oil (11.5 wt. %);
glycerin (11.4 wt. %);
monk fruit (2.8 wt. %); and
magnesium stearate (1.2 wt. %).

9. A method of supporting brain health or brain function, comprising:
administering, to a patient in need thereof, an effective amount of sterubin;
wherein the sterubin is administered in a form adapted for sublingual administration of a dosage of a composition of 300 mg;
wherein the composition contains:
sterubin-bio-concentrated, yerba santa (11.2 wt. %);
gamma aminobutyric acid (10.7 wt. %);
tauroursodeoxycholic acid (10.7 wt. %);
glutathione (9.7 wt. %);
nicotinamide mononucleotide (9.5 wt. %);
alpha-glyceryl phosphorylcholine (8.5 wt. %);
5-hydroxytryptophan (5.5 wt. %);
phosphatidylserine (4.8 wt. %);
star anis (2.5 wt. %);
omega oil (11.5 wt. %);
glycerin (11.4 wt. %);
monk fruit (2.8 wt. %); and
magnesium stearate (1.2 wt. %).

10. The method of claim 6 , wherein the composition is in a form of a chewable tablet or a spray for oral administration.

11. The method of claim 6 , wherein the composition is in a form of a pharmaceutical composition, a dietary supplement, or a health supplement.

12. The method of claim 8 , wherein the composition is in a form of a chewable tablet or a spray for oral administration.

13. The method of claim 8 , wherein the composition is in a form of a pharmaceutical composition, a dietary supplement, or a health supplement.

14. The method of claim 9 , wherein the composition is in a form of a chewable tablet or a spray for oral administration.

15. The method of claim 9 , wherein the composition is in a form of a pharmaceutical composition, a dietary supplement, or a health supplement.

Assignees

• Coe William B

Inventors

• Coe William B

Classifications

• A61K38/063 Primary

  Glutathione · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61K9/2068

  Compounds of unknown constitution, e.g. material from plants or animals (oils, fats, waxes, shellac A61K9/2013) · CPC title

• A61K9/205

  Polysaccharides, e.g. alginate, gums; Cyclodextrin · CPC title

• A61K47/12

  Carboxylic acids; Salts or anhydrides thereof · CPC title